BioCentury
ARTICLE | Clinical News

CC-115: Phase I data

June 13, 2016 7:00 AM UTC

Top-line data from 82 evaluable patients with relapsed or refractory advanced solid tumors and hematological malignancies in a 2-part, open-label, international Phase Ia/Ib trial showed that oral CC-1...